Table 3 Univariate Analysis for Overall Survival and Progression-free Survival
Number | Overall survival (months) | P value for OS | Progression-free survival (months) | P value for PFS | |
|---|---|---|---|---|---|
70 | 16.1 ± 11.2 | 6.2 ± 4.3 | |||
Sex | 0.64 | 0.16 | |||
Female | 34 | 15.6 ± 11.7 | 6.7 ± 4.6 | ||
Male | 36 | 16.6 ± 10.8 | 5.7 ± 3.9 | ||
Age | 0.02 | 0.28 | |||
< 60 | 44 | 18.7 ± 12.0 | 6.4 ± 4.6 | ||
> =60 | 26 | 11.7 ± 8.1 | 5.8 ± 3.8 | ||
KPS | 0.10 | 0.66 | |||
> =70 | 51 | 16.1 ± 11.9 | 6.2 ± 4.3 | ||
< 70 | 19 | 12.3 ± 8.0 | 6.7 ± 4.4 | ||
IESLG score | |||||
Low risk | 25 | 23.0 ± 12.8 | 0.001 | 7.5 ± 5.2 | 0.138 |
Intermediate risk | 32 | 13.6 ± 8.5 | 5.7 ± 3.4 | ||
High risk | 13 | 9.0 ± 6.1 | 4.8 ± 4.0 | ||
Duration of symptoms (months) | 0.21 | 0.22 | |||
> =1 | 53 | 16.7 ± 11.5 | 6.4 ± 4.6 | ||
< 1 | 17 | 14.2 ± 10.1 | 5.5 ± 3.1 | ||
Numbers of tumors | 0.99 | 0.98 | |||
Multiple | 32 | 10.6 ± 7.2 | 5.0 ± 4.0 | ||
Single | 38 | 20.8 ± 11.9 | 7.1 ± 4.3 | ||
The maximum diameter of the target | 0.25 | 0.10 | |||
> =30 | 38 | 16.9 ± 11.8 | 6.8 ± 4.8 | ||
< 30 | 32 | 15.1 ± 10.5 | 5.5 ± 3.6 | ||
Location | 0.00 | 0.00 | |||
Not deep location | 53 | 18.2 ± 11.7 | 6.9 ± 4.5 | ||
Deep location | 17 | 9.6 ± 6.1 | 3.8 ± 2.1 | ||
The operative type | 0.00 | 0.00 | |||
Biopsy | 42 | 11.2 ± 6.2 | 4.6 ± 3.2 | ||
Resection | 28 | 23.4 ± 13.0 | 8.6 ± 4.7 | ||
Changes in symptoms | 0.94 | 0.96 | |||
Not improvement | 54 | 14.9 ± 11.0 | 5.8 ± 4.0 | ||
Improvement | 16 | 20.0 ± 11.4 | 7.9 ± 4.9 | ||
Complication | 0.15 | 0.00 | |||
No | 58 | 16.7 ± 10.1 | 6.9 ± 4.3 | ||
Yes | 12 | 13.1 ± 15.8 | 2.8 ± 1.9 | ||